nodes	percent_of_prediction	percent_of_DWPC	metapath
Rosiglitazone—ACSL4—prostate cancer	0.335	0.777	CbGaD
Rosiglitazone—CYP2A6—prostate cancer	0.0563	0.131	CbGaD
Rosiglitazone—CYP2C19—prostate cancer	0.0396	0.0919	CbGaD
Rosiglitazone—SLCO1B1—Cabazitaxel—prostate cancer	0.0264	0.0739	CbGbCtD
Rosiglitazone—SLCO1B1—Estrone—prostate cancer	0.0258	0.0722	CbGbCtD
Rosiglitazone—ALB—Abiraterone—prostate cancer	0.0195	0.0547	CbGbCtD
Rosiglitazone—CYP2C8—Nilutamide—prostate cancer	0.0182	0.051	CbGbCtD
Rosiglitazone—SLCO1B1—Conjugated Estrogens—prostate cancer	0.0169	0.0472	CbGbCtD
Rosiglitazone—CYP2C19—Nilutamide—prostate cancer	0.0153	0.0428	CbGbCtD
Rosiglitazone—CYP2C19—Bicalutamide—prostate cancer	0.0153	0.0428	CbGbCtD
Rosiglitazone—CYP2C8—Abiraterone—prostate cancer	0.0151	0.0423	CbGbCtD
Rosiglitazone—SLCO1B1—Estradiol—prostate cancer	0.0148	0.0415	CbGbCtD
Rosiglitazone—ALB—Estrone—prostate cancer	0.0141	0.0395	CbGbCtD
Rosiglitazone—CYP2C9—Bicalutamide—prostate cancer	0.0127	0.0356	CbGbCtD
Rosiglitazone—CYP2C9—Nilutamide—prostate cancer	0.0127	0.0356	CbGbCtD
Rosiglitazone—CYP2C19—Flutamide—prostate cancer	0.0127	0.0355	CbGbCtD
Rosiglitazone—CYP1A2—Flutamide—prostate cancer	0.0117	0.0327	CbGbCtD
Rosiglitazone—CYP2D6—Bicalutamide—prostate cancer	0.0116	0.0325	CbGbCtD
Rosiglitazone—CYP2C8—Cabazitaxel—prostate cancer	0.0112	0.0313	CbGbCtD
Rosiglitazone—CYP2C8—Ethinyl Estradiol—prostate cancer	0.00973	0.0272	CbGbCtD
Rosiglitazone—CYP2D6—Abiraterone—prostate cancer	0.00963	0.027	CbGbCtD
Rosiglitazone—CYP1A2—Estrone—prostate cancer	0.00845	0.0237	CbGbCtD
Rosiglitazone—ALB—Estradiol—prostate cancer	0.00812	0.0227	CbGbCtD
Rosiglitazone—CYP2C9—Estrone—prostate cancer	0.00762	0.0213	CbGbCtD
Rosiglitazone—PTGS1—Etoposide—prostate cancer	0.0071	0.0199	CbGbCtD
Rosiglitazone—ALB—Prednisone—prostate cancer	0.00698	0.0195	CbGbCtD
Rosiglitazone—CYP2C8—Estradiol—prostate cancer	0.00627	0.0176	CbGbCtD
Rosiglitazone—CYP2C9—Capecitabine—prostate cancer	0.00577	0.0162	CbGbCtD
Rosiglitazone—CYP1A2—Conjugated Estrogens—prostate cancer	0.00553	0.0155	CbGbCtD
Rosiglitazone—CYP2C19—Estradiol—prostate cancer	0.00526	0.0147	CbGbCtD
Rosiglitazone—CYP1A2—Estradiol—prostate cancer	0.00486	0.0136	CbGbCtD
Rosiglitazone—CYP2C19—Prednisone—prostate cancer	0.00453	0.0127	CbGbCtD
Rosiglitazone—CYP2C9—Estradiol—prostate cancer	0.00437	0.0122	CbGbCtD
Rosiglitazone—CYP2C8—Etoposide—prostate cancer	0.0041	0.0115	CbGbCtD
Rosiglitazone—CYP1A2—Etoposide—prostate cancer	0.00317	0.00887	CbGbCtD
Rosiglitazone—ACSL4—prostate gland—prostate cancer	0.00192	0.0781	CbGeAlD
Rosiglitazone—CYP2C19—urine—prostate cancer	0.00182	0.074	CbGeAlD
Rosiglitazone—CYP2D6—Doxorubicin—prostate cancer	0.00178	0.00499	CbGbCtD
Rosiglitazone—ACSL4—seminal vesicle—prostate cancer	0.00162	0.0661	CbGeAlD
Rosiglitazone—CYP1A2—urine—prostate cancer	0.00148	0.0604	CbGeAlD
Rosiglitazone—CYP2C9—urine—prostate cancer	0.00141	0.0573	CbGeAlD
Rosiglitazone—ACSL4—renal system—prostate cancer	0.00131	0.0533	CbGeAlD
Rosiglitazone—ACSL4—urethra—prostate cancer	0.00128	0.0523	CbGeAlD
Rosiglitazone—CYP2D6—urine—prostate cancer	0.00106	0.043	CbGeAlD
Rosiglitazone—CYP2A6—prostate gland—prostate cancer	0.00101	0.0413	CbGeAlD
Rosiglitazone—ACSL4—bone marrow—prostate cancer	0.000989	0.0403	CbGeAlD
Rosiglitazone—PPARG—Teniposide—Etoposide—prostate cancer	0.000948	1	CbGdCrCtD
Rosiglitazone—PPARG—prostate gland—prostate cancer	0.000863	0.0351	CbGeAlD
Rosiglitazone—CYP2A6—seminal vesicle—prostate cancer	0.000857	0.0349	CbGeAlD
Rosiglitazone—ACSL4—testis—prostate cancer	0.000845	0.0344	CbGeAlD
Rosiglitazone—SLCO1B1—renal system—prostate cancer	0.000682	0.0278	CbGeAlD
Rosiglitazone—PPARG—epithelium—prostate cancer	0.000634	0.0258	CbGeAlD
Rosiglitazone—ACSL4—lymph node—prostate cancer	0.000613	0.0249	CbGeAlD
Rosiglitazone—PPARG—renal system—prostate cancer	0.000588	0.024	CbGeAlD
Rosiglitazone—PPARG—urethra—prostate cancer	0.000578	0.0235	CbGeAlD
Rosiglitazone—Pioglitazone—CYP2C19—prostate cancer	0.000489	0.434	CrCbGaD
Rosiglitazone—PTGS1—prostate gland—prostate cancer	0.000462	0.0188	CbGeAlD
Rosiglitazone—PPARG—bone marrow—prostate cancer	0.000445	0.0181	CbGeAlD
Rosiglitazone—PTGS1—seminal vesicle—prostate cancer	0.00039	0.0159	CbGeAlD
Rosiglitazone—CYP2C8—renal system—prostate cancer	0.000388	0.0158	CbGeAlD
Rosiglitazone—PPARG—testis—prostate cancer	0.00038	0.0155	CbGeAlD
Rosiglitazone—CYP1A2—renal system—prostate cancer	0.000363	0.0148	CbGeAlD
Rosiglitazone—ALB—testis—prostate cancer	0.000357	0.0145	CbGeAlD
Rosiglitazone—PTGS1—epithelium—prostate cancer	0.000339	0.0138	CbGeAlD
Rosiglitazone—Dofetilide—CYP3A4—prostate cancer	0.000326	0.29	CrCbGaD
Rosiglitazone—PTGS1—renal system—prostate cancer	0.000315	0.0128	CbGeAlD
Rosiglitazone—Pioglitazone—CYP3A4—prostate cancer	0.000311	0.276	CrCbGaD
Rosiglitazone—PPARG—lymph node—prostate cancer	0.000276	0.0112	CbGeAlD
Rosiglitazone—ALB—lymph node—prostate cancer	0.000259	0.0105	CbGeAlD
Rosiglitazone—CYP2D6—renal system—prostate cancer	0.000259	0.0105	CbGeAlD
Rosiglitazone—CYP2C8—testis—prostate cancer	0.000251	0.0102	CbGeAlD
Rosiglitazone—PTGS1—testis—prostate cancer	0.000203	0.00828	CbGeAlD
Rosiglitazone—CYP2D6—testis—prostate cancer	0.000167	0.0068	CbGeAlD
Rosiglitazone—PTGS1—lymph node—prostate cancer	0.000147	0.006	CbGeAlD
Rosiglitazone—Dermatitis—Ethinyl Estradiol—prostate cancer	7.99e-05	0.000803	CcSEcCtD
Rosiglitazone—Acute coronary syndrome—Capecitabine—prostate cancer	7.97e-05	0.000802	CcSEcCtD
Rosiglitazone—Headache—Ethinyl Estradiol—prostate cancer	7.94e-05	0.000799	CcSEcCtD
Rosiglitazone—Myocardial infarction—Capecitabine—prostate cancer	7.93e-05	0.000798	CcSEcCtD
Rosiglitazone—Hepatobiliary disease—Docetaxel—prostate cancer	7.9e-05	0.000795	CcSEcCtD
Rosiglitazone—Increased appetite—Epirubicin—prostate cancer	7.78e-05	0.000783	CcSEcCtD
Rosiglitazone—Diabetes mellitus—Doxorubicin—prostate cancer	7.78e-05	0.000782	CcSEcCtD
Rosiglitazone—Hepatic function abnormal—Doxorubicin—prostate cancer	7.74e-05	0.000779	CcSEcCtD
Rosiglitazone—Anaphylactic shock—Mitoxantrone—prostate cancer	7.71e-05	0.000775	CcSEcCtD
Rosiglitazone—Oedema—Mitoxantrone—prostate cancer	7.71e-05	0.000775	CcSEcCtD
Rosiglitazone—Infection—Mitoxantrone—prostate cancer	7.66e-05	0.00077	CcSEcCtD
Rosiglitazone—Hepatobiliary disease—Capecitabine—prostate cancer	7.65e-05	0.00077	CcSEcCtD
Rosiglitazone—Back pain—Etoposide—prostate cancer	7.6e-05	0.000764	CcSEcCtD
Rosiglitazone—Thrombocytopenia—Mitoxantrone—prostate cancer	7.55e-05	0.000759	CcSEcCtD
Rosiglitazone—Musculoskeletal discomfort—Estradiol—prostate cancer	7.54e-05	0.000758	CcSEcCtD
Rosiglitazone—Nausea—Ethinyl Estradiol—prostate cancer	7.53e-05	0.000758	CcSEcCtD
Rosiglitazone—Hepatic failure—Doxorubicin—prostate cancer	7.53e-05	0.000757	CcSEcCtD
Rosiglitazone—Hepatitis—Docetaxel—prostate cancer	7.5e-05	0.000754	CcSEcCtD
Rosiglitazone—Hypoglycaemia—Epirubicin—prostate cancer	7.49e-05	0.000754	CcSEcCtD
Rosiglitazone—Cardiac failure—Epirubicin—prostate cancer	7.49e-05	0.000754	CcSEcCtD
Rosiglitazone—Asthenia—Goserelin—prostate cancer	7.49e-05	0.000753	CcSEcCtD
Rosiglitazone—Cerebrovascular accident—Epirubicin—prostate cancer	7.46e-05	0.000751	CcSEcCtD
Rosiglitazone—Cardiac failure congestive—Doxorubicin—prostate cancer	7.46e-05	0.00075	CcSEcCtD
Rosiglitazone—Asthenia—Conjugated Estrogens—prostate cancer	7.42e-05	0.000746	CcSEcCtD
Rosiglitazone—Oedema peripheral—Docetaxel—prostate cancer	7.39e-05	0.000743	CcSEcCtD
Rosiglitazone—Pruritus—Goserelin—prostate cancer	7.38e-05	0.000743	CcSEcCtD
Rosiglitazone—Connective tissue disorder—Docetaxel—prostate cancer	7.37e-05	0.000741	CcSEcCtD
Rosiglitazone—Weight increased—Prednisone—prostate cancer	7.35e-05	0.00074	CcSEcCtD
Rosiglitazone—Pruritus—Conjugated Estrogens—prostate cancer	7.31e-05	0.000736	CcSEcCtD
Rosiglitazone—Hyperglycaemia—Prednisone—prostate cancer	7.29e-05	0.000733	CcSEcCtD
Rosiglitazone—Hepatitis—Capecitabine—prostate cancer	7.26e-05	0.00073	CcSEcCtD
Rosiglitazone—Anaemia—Etoposide—prostate cancer	7.26e-05	0.00073	CcSEcCtD
Rosiglitazone—Increased appetite—Doxorubicin—prostate cancer	7.2e-05	0.000724	CcSEcCtD
Rosiglitazone—Oedema peripheral—Capecitabine—prostate cancer	7.15e-05	0.00072	CcSEcCtD
Rosiglitazone—Gastrointestinal disorder—Estradiol—prostate cancer	7.14e-05	0.000718	CcSEcCtD
Rosiglitazone—Diarrhoea—Goserelin—prostate cancer	7.14e-05	0.000718	CcSEcCtD
Rosiglitazone—Connective tissue disorder—Capecitabine—prostate cancer	7.14e-05	0.000718	CcSEcCtD
Rosiglitazone—Fatigue—Estradiol—prostate cancer	7.13e-05	0.000717	CcSEcCtD
Rosiglitazone—Acute coronary syndrome—Prednisone—prostate cancer	7.1e-05	0.000714	CcSEcCtD
Rosiglitazone—Erythema multiforme—Docetaxel—prostate cancer	7.09e-05	0.000713	CcSEcCtD
Rosiglitazone—Constipation—Estradiol—prostate cancer	7.07e-05	0.000712	CcSEcCtD
Rosiglitazone—Diarrhoea—Conjugated Estrogens—prostate cancer	7.07e-05	0.000711	CcSEcCtD
Rosiglitazone—Myocardial infarction—Prednisone—prostate cancer	7.06e-05	0.00071	CcSEcCtD
Rosiglitazone—Leukopenia—Etoposide—prostate cancer	7.03e-05	0.000707	CcSEcCtD
Rosiglitazone—Musculoskeletal discomfort—Mitoxantrone—prostate cancer	7.02e-05	0.000706	CcSEcCtD
Rosiglitazone—Eye disorder—Docetaxel—prostate cancer	7.01e-05	0.000705	CcSEcCtD
Rosiglitazone—Cardiac disorder—Docetaxel—prostate cancer	6.96e-05	0.0007	CcSEcCtD
Rosiglitazone—Hypoglycaemia—Doxorubicin—prostate cancer	6.93e-05	0.000697	CcSEcCtD
Rosiglitazone—Cardiac failure—Doxorubicin—prostate cancer	6.93e-05	0.000697	CcSEcCtD
Rosiglitazone—Cerebrovascular accident—Doxorubicin—prostate cancer	6.9e-05	0.000695	CcSEcCtD
Rosiglitazone—Dizziness—Goserelin—prostate cancer	6.9e-05	0.000694	CcSEcCtD
Rosiglitazone—Erythema multiforme—Capecitabine—prostate cancer	6.87e-05	0.000691	CcSEcCtD
Rosiglitazone—Dizziness—Conjugated Estrogens—prostate cancer	6.83e-05	0.000688	CcSEcCtD
Rosiglitazone—Eye disorder—Capecitabine—prostate cancer	6.79e-05	0.000683	CcSEcCtD
Rosiglitazone—Hypertension—Etoposide—prostate cancer	6.78e-05	0.000682	CcSEcCtD
Rosiglitazone—Immune system disorder—Docetaxel—prostate cancer	6.77e-05	0.000681	CcSEcCtD
Rosiglitazone—Cardiac disorder—Capecitabine—prostate cancer	6.74e-05	0.000678	CcSEcCtD
Rosiglitazone—Fatigue—Mitoxantrone—prostate cancer	6.65e-05	0.000668	CcSEcCtD
Rosiglitazone—Constipation—Mitoxantrone—prostate cancer	6.59e-05	0.000663	CcSEcCtD
Rosiglitazone—Rash—Goserelin—prostate cancer	6.58e-05	0.000662	CcSEcCtD
Rosiglitazone—Dermatitis—Goserelin—prostate cancer	6.57e-05	0.000661	CcSEcCtD
Rosiglitazone—Urticaria—Estradiol—prostate cancer	6.57e-05	0.000661	CcSEcCtD
Rosiglitazone—Immune system disorder—Capecitabine—prostate cancer	6.56e-05	0.00066	CcSEcCtD
Rosiglitazone—Nasopharyngitis—Epirubicin—prostate cancer	6.54e-05	0.000658	CcSEcCtD
Rosiglitazone—Headache—Goserelin—prostate cancer	6.54e-05	0.000658	CcSEcCtD
Rosiglitazone—Malnutrition—Docetaxel—prostate cancer	6.53e-05	0.000657	CcSEcCtD
Rosiglitazone—Rash—Conjugated Estrogens—prostate cancer	6.52e-05	0.000656	CcSEcCtD
Rosiglitazone—Dermatitis—Conjugated Estrogens—prostate cancer	6.51e-05	0.000655	CcSEcCtD
Rosiglitazone—Headache—Conjugated Estrogens—prostate cancer	6.48e-05	0.000651	CcSEcCtD
Rosiglitazone—Anaphylactic shock—Etoposide—prostate cancer	6.41e-05	0.000645	CcSEcCtD
Rosiglitazone—Infection—Etoposide—prostate cancer	6.37e-05	0.000641	CcSEcCtD
Rosiglitazone—Connective tissue disorder—Prednisone—prostate cancer	6.36e-05	0.000639	CcSEcCtD
Rosiglitazone—Malnutrition—Capecitabine—prostate cancer	6.32e-05	0.000636	CcSEcCtD
Rosiglitazone—Back pain—Docetaxel—prostate cancer	6.32e-05	0.000635	CcSEcCtD
Rosiglitazone—Thrombocytopenia—Etoposide—prostate cancer	6.28e-05	0.000631	CcSEcCtD
Rosiglitazone—Nausea—Goserelin—prostate cancer	6.2e-05	0.000623	CcSEcCtD
Rosiglitazone—Nausea—Conjugated Estrogens—prostate cancer	6.14e-05	0.000618	CcSEcCtD
Rosiglitazone—Urticaria—Mitoxantrone—prostate cancer	6.12e-05	0.000616	CcSEcCtD
Rosiglitazone—Back pain—Capecitabine—prostate cancer	6.11e-05	0.000615	CcSEcCtD
Rosiglitazone—Nasopharyngitis—Doxorubicin—prostate cancer	6.05e-05	0.000609	CcSEcCtD
Rosiglitazone—Eye disorder—Prednisone—prostate cancer	6.04e-05	0.000608	CcSEcCtD
Rosiglitazone—Anaemia—Docetaxel—prostate cancer	6.03e-05	0.000607	CcSEcCtD
Rosiglitazone—Asthenia—Estradiol—prostate cancer	5.94e-05	0.000597	CcSEcCtD
Rosiglitazone—Upper respiratory tract infection—Epirubicin—prostate cancer	5.87e-05	0.000591	CcSEcCtD
Rosiglitazone—Pruritus—Estradiol—prostate cancer	5.85e-05	0.000589	CcSEcCtD
Rosiglitazone—Leukopenia—Docetaxel—prostate cancer	5.84e-05	0.000588	CcSEcCtD
Rosiglitazone—Anaemia—Capecitabine—prostate cancer	5.84e-05	0.000588	CcSEcCtD
Rosiglitazone—Immune system disorder—Prednisone—prostate cancer	5.84e-05	0.000588	CcSEcCtD
Rosiglitazone—Weight increased—Epirubicin—prostate cancer	5.75e-05	0.000579	CcSEcCtD
Rosiglitazone—Hyperglycaemia—Epirubicin—prostate cancer	5.7e-05	0.000573	CcSEcCtD
Rosiglitazone—Diarrhoea—Estradiol—prostate cancer	5.66e-05	0.000569	CcSEcCtD
Rosiglitazone—Leukopenia—Capecitabine—prostate cancer	5.66e-05	0.000569	CcSEcCtD
Rosiglitazone—Hypertension—Docetaxel—prostate cancer	5.64e-05	0.000567	CcSEcCtD
Rosiglitazone—Malnutrition—Prednisone—prostate cancer	5.63e-05	0.000566	CcSEcCtD
Rosiglitazone—Stevens-Johnson syndrome—Epirubicin—prostate cancer	5.59e-05	0.000562	CcSEcCtD
Rosiglitazone—Myalgia—Docetaxel—prostate cancer	5.56e-05	0.000559	CcSEcCtD
Rosiglitazone—Arthralgia—Docetaxel—prostate cancer	5.56e-05	0.000559	CcSEcCtD
Rosiglitazone—Gastrointestinal disorder—Etoposide—prostate cancer	5.54e-05	0.000557	CcSEcCtD
Rosiglitazone—Asthenia—Mitoxantrone—prostate cancer	5.53e-05	0.000556	CcSEcCtD
Rosiglitazone—Fatigue—Etoposide—prostate cancer	5.53e-05	0.000556	CcSEcCtD
Rosiglitazone—Constipation—Etoposide—prostate cancer	5.48e-05	0.000552	CcSEcCtD
Rosiglitazone—Dizziness—Estradiol—prostate cancer	5.47e-05	0.00055	CcSEcCtD
Rosiglitazone—Hypertension—Capecitabine—prostate cancer	5.46e-05	0.000549	CcSEcCtD
Rosiglitazone—Upper respiratory tract infection—Doxorubicin—prostate cancer	5.43e-05	0.000547	CcSEcCtD
Rosiglitazone—Myalgia—Capecitabine—prostate cancer	5.38e-05	0.000541	CcSEcCtD
Rosiglitazone—Arthralgia—Capecitabine—prostate cancer	5.38e-05	0.000541	CcSEcCtD
Rosiglitazone—Hepatobiliary disease—Epirubicin—prostate cancer	5.33e-05	0.000536	CcSEcCtD
Rosiglitazone—Anaphylactic shock—Docetaxel—prostate cancer	5.33e-05	0.000536	CcSEcCtD
Rosiglitazone—Oedema—Docetaxel—prostate cancer	5.33e-05	0.000536	CcSEcCtD
Rosiglitazone—Weight increased—Doxorubicin—prostate cancer	5.32e-05	0.000535	CcSEcCtD
Rosiglitazone—Infection—Docetaxel—prostate cancer	5.29e-05	0.000532	CcSEcCtD
Rosiglitazone—Sinusitis—Epirubicin—prostate cancer	5.29e-05	0.000532	CcSEcCtD
Rosiglitazone—Hyperglycaemia—Doxorubicin—prostate cancer	5.27e-05	0.000531	CcSEcCtD
Rosiglitazone—Diarrhoea—Mitoxantrone—prostate cancer	5.27e-05	0.000531	CcSEcCtD
Rosiglitazone—Nervous system disorder—Docetaxel—prostate cancer	5.23e-05	0.000526	CcSEcCtD
Rosiglitazone—Thrombocytopenia—Docetaxel—prostate cancer	5.22e-05	0.000525	CcSEcCtD
Rosiglitazone—Rash—Estradiol—prostate cancer	5.22e-05	0.000525	CcSEcCtD
Rosiglitazone—Dermatitis—Estradiol—prostate cancer	5.21e-05	0.000524	CcSEcCtD
Rosiglitazone—Anaemia—Prednisone—prostate cancer	5.2e-05	0.000523	CcSEcCtD
Rosiglitazone—Headache—Estradiol—prostate cancer	5.18e-05	0.000521	CcSEcCtD
Rosiglitazone—Stevens-Johnson syndrome—Doxorubicin—prostate cancer	5.17e-05	0.00052	CcSEcCtD
Rosiglitazone—Oedema—Capecitabine—prostate cancer	5.16e-05	0.000519	CcSEcCtD
Rosiglitazone—Angioedema—Prednisone—prostate cancer	5.14e-05	0.000518	CcSEcCtD
Rosiglitazone—Infection—Capecitabine—prostate cancer	5.12e-05	0.000516	CcSEcCtD
Rosiglitazone—Urticaria—Etoposide—prostate cancer	5.09e-05	0.000512	CcSEcCtD
Rosiglitazone—Nervous system disorder—Capecitabine—prostate cancer	5.06e-05	0.000509	CcSEcCtD
Rosiglitazone—Hepatitis—Epirubicin—prostate cancer	5.06e-05	0.000509	CcSEcCtD
Rosiglitazone—Thrombocytopenia—Capecitabine—prostate cancer	5.05e-05	0.000508	CcSEcCtD
Rosiglitazone—Oedema peripheral—Epirubicin—prostate cancer	4.98e-05	0.000501	CcSEcCtD
Rosiglitazone—Connective tissue disorder—Epirubicin—prostate cancer	4.97e-05	0.0005	CcSEcCtD
Rosiglitazone—Hepatobiliary disease—Doxorubicin—prostate cancer	4.93e-05	0.000496	CcSEcCtD
Rosiglitazone—Nausea—Estradiol—prostate cancer	4.91e-05	0.000494	CcSEcCtD
Rosiglitazone—Sinusitis—Doxorubicin—prostate cancer	4.89e-05	0.000492	CcSEcCtD
Rosiglitazone—Hypertension—Prednisone—prostate cancer	4.86e-05	0.000489	CcSEcCtD
Rosiglitazone—Rash—Mitoxantrone—prostate cancer	4.86e-05	0.000489	CcSEcCtD
Rosiglitazone—Dermatitis—Mitoxantrone—prostate cancer	4.86e-05	0.000488	CcSEcCtD
Rosiglitazone—Musculoskeletal discomfort—Docetaxel—prostate cancer	4.85e-05	0.000488	CcSEcCtD
Rosiglitazone—Headache—Mitoxantrone—prostate cancer	4.83e-05	0.000486	CcSEcCtD
Rosiglitazone—Arthralgia—Prednisone—prostate cancer	4.79e-05	0.000482	CcSEcCtD
Rosiglitazone—Myalgia—Prednisone—prostate cancer	4.79e-05	0.000482	CcSEcCtD
Rosiglitazone—Erythema multiforme—Epirubicin—prostate cancer	4.78e-05	0.000481	CcSEcCtD
Rosiglitazone—Eye disorder—Epirubicin—prostate cancer	4.73e-05	0.000476	CcSEcCtD
Rosiglitazone—Musculoskeletal discomfort—Capecitabine—prostate cancer	4.7e-05	0.000473	CcSEcCtD
Rosiglitazone—Cardiac disorder—Epirubicin—prostate cancer	4.69e-05	0.000472	CcSEcCtD
Rosiglitazone—Hepatitis—Doxorubicin—prostate cancer	4.68e-05	0.000471	CcSEcCtD
Rosiglitazone—Oedema peripheral—Doxorubicin—prostate cancer	4.61e-05	0.000464	CcSEcCtD
Rosiglitazone—Gastrointestinal disorder—Docetaxel—prostate cancer	4.6e-05	0.000463	CcSEcCtD
Rosiglitazone—Asthenia—Etoposide—prostate cancer	4.6e-05	0.000463	CcSEcCtD
Rosiglitazone—Connective tissue disorder—Doxorubicin—prostate cancer	4.6e-05	0.000463	CcSEcCtD
Rosiglitazone—Anaphylactic shock—Prednisone—prostate cancer	4.6e-05	0.000462	CcSEcCtD
Rosiglitazone—Oedema—Prednisone—prostate cancer	4.6e-05	0.000462	CcSEcCtD
Rosiglitazone—Fatigue—Docetaxel—prostate cancer	4.59e-05	0.000462	CcSEcCtD
Rosiglitazone—Nausea—Mitoxantrone—prostate cancer	4.58e-05	0.000461	CcSEcCtD
Rosiglitazone—Immune system disorder—Epirubicin—prostate cancer	4.57e-05	0.00046	CcSEcCtD
Rosiglitazone—Infection—Prednisone—prostate cancer	4.57e-05	0.000459	CcSEcCtD
Rosiglitazone—Constipation—Docetaxel—prostate cancer	4.56e-05	0.000458	CcSEcCtD
Rosiglitazone—Pruritus—Etoposide—prostate cancer	4.54e-05	0.000456	CcSEcCtD
Rosiglitazone—Nervous system disorder—Prednisone—prostate cancer	4.51e-05	0.000453	CcSEcCtD
Rosiglitazone—Gastrointestinal disorder—Capecitabine—prostate cancer	4.45e-05	0.000448	CcSEcCtD
Rosiglitazone—Fatigue—Capecitabine—prostate cancer	4.45e-05	0.000447	CcSEcCtD
Rosiglitazone—Erythema multiforme—Doxorubicin—prostate cancer	4.43e-05	0.000445	CcSEcCtD
Rosiglitazone—Constipation—Capecitabine—prostate cancer	4.41e-05	0.000444	CcSEcCtD
Rosiglitazone—Malnutrition—Epirubicin—prostate cancer	4.4e-05	0.000443	CcSEcCtD
Rosiglitazone—Diarrhoea—Etoposide—prostate cancer	4.39e-05	0.000441	CcSEcCtD
Rosiglitazone—Eye disorder—Doxorubicin—prostate cancer	4.37e-05	0.00044	CcSEcCtD
Rosiglitazone—Cardiac disorder—Doxorubicin—prostate cancer	4.34e-05	0.000437	CcSEcCtD
Rosiglitazone—Back pain—Epirubicin—prostate cancer	4.26e-05	0.000428	CcSEcCtD
Rosiglitazone—Dizziness—Etoposide—prostate cancer	4.24e-05	0.000426	CcSEcCtD
Rosiglitazone—Immune system disorder—Doxorubicin—prostate cancer	4.23e-05	0.000425	CcSEcCtD
Rosiglitazone—Musculoskeletal discomfort—Prednisone—prostate cancer	4.19e-05	0.000421	CcSEcCtD
Rosiglitazone—Urticaria—Capecitabine—prostate cancer	4.1e-05	0.000412	CcSEcCtD
Rosiglitazone—Malnutrition—Doxorubicin—prostate cancer	4.07e-05	0.00041	CcSEcCtD
Rosiglitazone—Anaemia—Epirubicin—prostate cancer	4.07e-05	0.000409	CcSEcCtD
Rosiglitazone—Rash—Etoposide—prostate cancer	4.04e-05	0.000407	CcSEcCtD
Rosiglitazone—Dermatitis—Etoposide—prostate cancer	4.04e-05	0.000406	CcSEcCtD
Rosiglitazone—Headache—Etoposide—prostate cancer	4.02e-05	0.000404	CcSEcCtD
Rosiglitazone—Fatigue—Prednisone—prostate cancer	3.96e-05	0.000399	CcSEcCtD
Rosiglitazone—Leukopenia—Epirubicin—prostate cancer	3.94e-05	0.000397	CcSEcCtD
Rosiglitazone—Back pain—Doxorubicin—prostate cancer	3.94e-05	0.000396	CcSEcCtD
Rosiglitazone—Constipation—Prednisone—prostate cancer	3.93e-05	0.000395	CcSEcCtD
Rosiglitazone—Asthenia—Docetaxel—prostate cancer	3.82e-05	0.000385	CcSEcCtD
Rosiglitazone—Nausea—Etoposide—prostate cancer	3.81e-05	0.000383	CcSEcCtD
Rosiglitazone—Hypertension—Epirubicin—prostate cancer	3.8e-05	0.000382	CcSEcCtD
Rosiglitazone—Pruritus—Docetaxel—prostate cancer	3.77e-05	0.000379	CcSEcCtD
Rosiglitazone—Anaemia—Doxorubicin—prostate cancer	3.77e-05	0.000379	CcSEcCtD
Rosiglitazone—Arthralgia—Epirubicin—prostate cancer	3.75e-05	0.000377	CcSEcCtD
Rosiglitazone—Myalgia—Epirubicin—prostate cancer	3.75e-05	0.000377	CcSEcCtD
Rosiglitazone—Asthenia—Capecitabine—prostate cancer	3.7e-05	0.000372	CcSEcCtD
Rosiglitazone—Urticaria—Prednisone—prostate cancer	3.65e-05	0.000367	CcSEcCtD
Rosiglitazone—Pruritus—Capecitabine—prostate cancer	3.65e-05	0.000367	CcSEcCtD
Rosiglitazone—Leukopenia—Doxorubicin—prostate cancer	3.65e-05	0.000367	CcSEcCtD
Rosiglitazone—Diarrhoea—Docetaxel—prostate cancer	3.65e-05	0.000367	CcSEcCtD
Rosiglitazone—Anaphylactic shock—Epirubicin—prostate cancer	3.59e-05	0.000362	CcSEcCtD
Rosiglitazone—Oedema—Epirubicin—prostate cancer	3.59e-05	0.000362	CcSEcCtD
Rosiglitazone—Infection—Epirubicin—prostate cancer	3.57e-05	0.000359	CcSEcCtD
Rosiglitazone—Diarrhoea—Capecitabine—prostate cancer	3.53e-05	0.000355	CcSEcCtD
Rosiglitazone—Nervous system disorder—Epirubicin—prostate cancer	3.52e-05	0.000355	CcSEcCtD
Rosiglitazone—Dizziness—Docetaxel—prostate cancer	3.52e-05	0.000354	CcSEcCtD
Rosiglitazone—Thrombocytopenia—Epirubicin—prostate cancer	3.52e-05	0.000354	CcSEcCtD
Rosiglitazone—Hypertension—Doxorubicin—prostate cancer	3.52e-05	0.000354	CcSEcCtD
Rosiglitazone—Myalgia—Doxorubicin—prostate cancer	3.47e-05	0.000349	CcSEcCtD
Rosiglitazone—Arthralgia—Doxorubicin—prostate cancer	3.47e-05	0.000349	CcSEcCtD
Rosiglitazone—Dizziness—Capecitabine—prostate cancer	3.41e-05	0.000343	CcSEcCtD
Rosiglitazone—Rash—Docetaxel—prostate cancer	3.36e-05	0.000338	CcSEcCtD
Rosiglitazone—Dermatitis—Docetaxel—prostate cancer	3.36e-05	0.000338	CcSEcCtD
Rosiglitazone—Headache—Docetaxel—prostate cancer	3.34e-05	0.000336	CcSEcCtD
Rosiglitazone—Anaphylactic shock—Doxorubicin—prostate cancer	3.33e-05	0.000335	CcSEcCtD
Rosiglitazone—Oedema—Doxorubicin—prostate cancer	3.33e-05	0.000335	CcSEcCtD
Rosiglitazone—Infection—Doxorubicin—prostate cancer	3.3e-05	0.000332	CcSEcCtD
Rosiglitazone—Asthenia—Prednisone—prostate cancer	3.3e-05	0.000332	CcSEcCtD
Rosiglitazone—Musculoskeletal discomfort—Epirubicin—prostate cancer	3.27e-05	0.000329	CcSEcCtD
Rosiglitazone—Nervous system disorder—Doxorubicin—prostate cancer	3.26e-05	0.000328	CcSEcCtD
Rosiglitazone—Thrombocytopenia—Doxorubicin—prostate cancer	3.26e-05	0.000328	CcSEcCtD
Rosiglitazone—Rash—Capecitabine—prostate cancer	3.25e-05	0.000327	CcSEcCtD
Rosiglitazone—Pruritus—Prednisone—prostate cancer	3.25e-05	0.000327	CcSEcCtD
Rosiglitazone—Dermatitis—Capecitabine—prostate cancer	3.25e-05	0.000327	CcSEcCtD
Rosiglitazone—Headache—Capecitabine—prostate cancer	3.23e-05	0.000325	CcSEcCtD
Rosiglitazone—Nausea—Docetaxel—prostate cancer	3.16e-05	0.000318	CcSEcCtD
Rosiglitazone—Diarrhoea—Prednisone—prostate cancer	3.14e-05	0.000316	CcSEcCtD
Rosiglitazone—Gastrointestinal disorder—Epirubicin—prostate cancer	3.1e-05	0.000312	CcSEcCtD
Rosiglitazone—Fatigue—Epirubicin—prostate cancer	3.1e-05	0.000312	CcSEcCtD
Rosiglitazone—Constipation—Epirubicin—prostate cancer	3.07e-05	0.000309	CcSEcCtD
Rosiglitazone—Nausea—Capecitabine—prostate cancer	3.06e-05	0.000308	CcSEcCtD
Rosiglitazone—Dizziness—Prednisone—prostate cancer	3.04e-05	0.000306	CcSEcCtD
Rosiglitazone—Musculoskeletal discomfort—Doxorubicin—prostate cancer	3.03e-05	0.000305	CcSEcCtD
Rosiglitazone—Rash—Prednisone—prostate cancer	2.9e-05	0.000291	CcSEcCtD
Rosiglitazone—Dermatitis—Prednisone—prostate cancer	2.89e-05	0.000291	CcSEcCtD
Rosiglitazone—Headache—Prednisone—prostate cancer	2.88e-05	0.00029	CcSEcCtD
Rosiglitazone—Gastrointestinal disorder—Doxorubicin—prostate cancer	2.87e-05	0.000289	CcSEcCtD
Rosiglitazone—Fatigue—Doxorubicin—prostate cancer	2.87e-05	0.000288	CcSEcCtD
Rosiglitazone—Urticaria—Epirubicin—prostate cancer	2.86e-05	0.000287	CcSEcCtD
Rosiglitazone—Constipation—Doxorubicin—prostate cancer	2.84e-05	0.000286	CcSEcCtD
Rosiglitazone—Nausea—Prednisone—prostate cancer	2.73e-05	0.000275	CcSEcCtD
Rosiglitazone—Urticaria—Doxorubicin—prostate cancer	2.64e-05	0.000266	CcSEcCtD
Rosiglitazone—Asthenia—Epirubicin—prostate cancer	2.58e-05	0.000259	CcSEcCtD
Rosiglitazone—Pruritus—Epirubicin—prostate cancer	2.54e-05	0.000256	CcSEcCtD
Rosiglitazone—Diarrhoea—Epirubicin—prostate cancer	2.46e-05	0.000247	CcSEcCtD
Rosiglitazone—Asthenia—Doxorubicin—prostate cancer	2.39e-05	0.00024	CcSEcCtD
Rosiglitazone—Dizziness—Epirubicin—prostate cancer	2.38e-05	0.000239	CcSEcCtD
Rosiglitazone—Pruritus—Doxorubicin—prostate cancer	2.35e-05	0.000237	CcSEcCtD
Rosiglitazone—Diarrhoea—Doxorubicin—prostate cancer	2.28e-05	0.000229	CcSEcCtD
Rosiglitazone—Rash—Epirubicin—prostate cancer	2.27e-05	0.000228	CcSEcCtD
Rosiglitazone—Dermatitis—Epirubicin—prostate cancer	2.26e-05	0.000228	CcSEcCtD
Rosiglitazone—Headache—Epirubicin—prostate cancer	2.25e-05	0.000226	CcSEcCtD
Rosiglitazone—Dizziness—Doxorubicin—prostate cancer	2.2e-05	0.000221	CcSEcCtD
Rosiglitazone—Nausea—Epirubicin—prostate cancer	2.13e-05	0.000215	CcSEcCtD
Rosiglitazone—Rash—Doxorubicin—prostate cancer	2.1e-05	0.000211	CcSEcCtD
Rosiglitazone—Dermatitis—Doxorubicin—prostate cancer	2.09e-05	0.000211	CcSEcCtD
Rosiglitazone—Headache—Doxorubicin—prostate cancer	2.08e-05	0.00021	CcSEcCtD
Rosiglitazone—Nausea—Doxorubicin—prostate cancer	1.98e-05	0.000199	CcSEcCtD
Rosiglitazone—CYP2D6—Metabolism—NCOA2—prostate cancer	1.97e-06	2.29e-05	CbGpPWpGaD
Rosiglitazone—PPARG—Gene Expression—MYC—prostate cancer	1.97e-06	2.29e-05	CbGpPWpGaD
Rosiglitazone—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CG—prostate cancer	1.97e-06	2.28e-05	CbGpPWpGaD
Rosiglitazone—CYP2C9—Metabolism—NCOA2—prostate cancer	1.96e-06	2.27e-05	CbGpPWpGaD
Rosiglitazone—ALB—Hemostasis—EP300—prostate cancer	1.95e-06	2.26e-05	CbGpPWpGaD
Rosiglitazone—PTGS1—Metabolism—PIK3CG—prostate cancer	1.95e-06	2.26e-05	CbGpPWpGaD
Rosiglitazone—CYP2C19—Metabolism—TH—prostate cancer	1.95e-06	2.26e-05	CbGpPWpGaD
Rosiglitazone—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CB—prostate cancer	1.94e-06	2.25e-05	CbGpPWpGaD
Rosiglitazone—SLCO1B1—Metabolism—PIK3CD—prostate cancer	1.93e-06	2.24e-05	CbGpPWpGaD
Rosiglitazone—CYP2C19—Metabolism—CYP3A4—prostate cancer	1.93e-06	2.24e-05	CbGpPWpGaD
Rosiglitazone—CYP2C8—Metabolism—RXRA—prostate cancer	1.93e-06	2.23e-05	CbGpPWpGaD
Rosiglitazone—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—prostate cancer	1.92e-06	2.22e-05	CbGpPWpGaD
Rosiglitazone—ALB—Metabolism—RXRA—prostate cancer	1.92e-06	2.22e-05	CbGpPWpGaD
Rosiglitazone—CYP1A2—Metabolism—HPGDS—prostate cancer	1.91e-06	2.22e-05	CbGpPWpGaD
Rosiglitazone—CYP1A2—Metabolism—CYP2C19—prostate cancer	1.9e-06	2.2e-05	CbGpPWpGaD
Rosiglitazone—ALB—Hemostasis—SRC—prostate cancer	1.9e-06	2.2e-05	CbGpPWpGaD
Rosiglitazone—CYP2C19—Metabolism—CYP1B1—prostate cancer	1.9e-06	2.2e-05	CbGpPWpGaD
Rosiglitazone—CYP2D6—Metabolism—SLC5A5—prostate cancer	1.88e-06	2.18e-05	CbGpPWpGaD
Rosiglitazone—CYP2C8—Metabolism of lipids and lipoproteins—PTEN—prostate cancer	1.87e-06	2.17e-05	CbGpPWpGaD
Rosiglitazone—CYP2C9—Metabolism—SLC5A5—prostate cancer	1.87e-06	2.16e-05	CbGpPWpGaD
Rosiglitazone—ALB—Metabolism of lipids and lipoproteins—PTEN—prostate cancer	1.86e-06	2.16e-05	CbGpPWpGaD
Rosiglitazone—CYP2C8—Metabolism—COMT—prostate cancer	1.86e-06	2.15e-05	CbGpPWpGaD
Rosiglitazone—CYP1A2—Metabolism—ACHE—prostate cancer	1.85e-06	2.15e-05	CbGpPWpGaD
Rosiglitazone—CYP1A2—Metabolism—GSTT1—prostate cancer	1.85e-06	2.15e-05	CbGpPWpGaD
Rosiglitazone—ALB—Hemostasis—VEGFA—prostate cancer	1.85e-06	2.14e-05	CbGpPWpGaD
Rosiglitazone—CYP2C8—Metabolism—GSTP1—prostate cancer	1.85e-06	2.14e-05	CbGpPWpGaD
Rosiglitazone—PTGS1—Metabolism—INS—prostate cancer	1.85e-06	2.14e-05	CbGpPWpGaD
Rosiglitazone—ALB—Metabolism—COMT—prostate cancer	1.85e-06	2.14e-05	CbGpPWpGaD
Rosiglitazone—CYP2A6—Metabolism—PIK3CG—prostate cancer	1.85e-06	2.14e-05	CbGpPWpGaD
Rosiglitazone—PPARG—Metabolism—PTEN—prostate cancer	1.85e-06	2.14e-05	CbGpPWpGaD
Rosiglitazone—CYP2D6—Metabolism—CYP2E1—prostate cancer	1.84e-06	2.13e-05	CbGpPWpGaD
Rosiglitazone—ALB—Metabolism—GSTP1—prostate cancer	1.84e-06	2.13e-05	CbGpPWpGaD
Rosiglitazone—CYP2C19—Metabolism—GGT1—prostate cancer	1.84e-06	2.13e-05	CbGpPWpGaD
Rosiglitazone—CYP1A2—Metabolism—CYP2A6—prostate cancer	1.83e-06	2.12e-05	CbGpPWpGaD
Rosiglitazone—CYP1A2—Metabolism of lipids and lipoproteins—CREBBP—prostate cancer	1.83e-06	2.12e-05	CbGpPWpGaD
Rosiglitazone—CYP2C9—Metabolism—CYP2E1—prostate cancer	1.82e-06	2.11e-05	CbGpPWpGaD
Rosiglitazone—SLCO1B1—Metabolism—NOS3—prostate cancer	1.82e-06	2.11e-05	CbGpPWpGaD
Rosiglitazone—CYP2D6—Metabolism—NQO1—prostate cancer	1.82e-06	2.11e-05	CbGpPWpGaD
Rosiglitazone—CYP2C8—Metabolism—ITPR1—prostate cancer	1.82e-06	2.11e-05	CbGpPWpGaD
Rosiglitazone—PTGS1—Metabolism—CREBBP—prostate cancer	1.81e-06	2.1e-05	CbGpPWpGaD
Rosiglitazone—CYP2C19—Metabolism—NCOA1—prostate cancer	1.81e-06	2.1e-05	CbGpPWpGaD
Rosiglitazone—ALB—Metabolism—ITPR1—prostate cancer	1.81e-06	2.1e-05	CbGpPWpGaD
Rosiglitazone—CYP2C9—Metabolism—NQO1—prostate cancer	1.8e-06	2.09e-05	CbGpPWpGaD
Rosiglitazone—CYP2D6—Metabolism—TH—prostate cancer	1.79e-06	2.08e-05	CbGpPWpGaD
Rosiglitazone—CYP2C8—Metabolism of lipids and lipoproteins—EP300—prostate cancer	1.79e-06	2.07e-05	CbGpPWpGaD
Rosiglitazone—CYP1A2—Metabolism—AKR1C3—prostate cancer	1.78e-06	2.07e-05	CbGpPWpGaD
Rosiglitazone—CYP2C19—Metabolism—CYP19A1—prostate cancer	1.78e-06	2.07e-05	CbGpPWpGaD
Rosiglitazone—ALB—Metabolism of lipids and lipoproteins—EP300—prostate cancer	1.78e-06	2.06e-05	CbGpPWpGaD
Rosiglitazone—CYP2C9—Metabolism—TH—prostate cancer	1.78e-06	2.06e-05	CbGpPWpGaD
Rosiglitazone—CYP2D6—Metabolism—CYP3A4—prostate cancer	1.77e-06	2.06e-05	CbGpPWpGaD
Rosiglitazone—CYP1A2—Metabolism—PRKACB—prostate cancer	1.77e-06	2.06e-05	CbGpPWpGaD
Rosiglitazone—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CB—prostate cancer	1.77e-06	2.05e-05	CbGpPWpGaD
Rosiglitazone—PPARG—Metabolism—EP300—prostate cancer	1.76e-06	2.04e-05	CbGpPWpGaD
Rosiglitazone—CYP2C9—Metabolism—CYP3A4—prostate cancer	1.76e-06	2.04e-05	CbGpPWpGaD
Rosiglitazone—CYP1A2—Metabolism—CYP17A1—prostate cancer	1.76e-06	2.03e-05	CbGpPWpGaD
Rosiglitazone—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—prostate cancer	1.75e-06	2.03e-05	CbGpPWpGaD
Rosiglitazone—CYP2A6—Metabolism—INS—prostate cancer	1.75e-06	2.03e-05	CbGpPWpGaD
Rosiglitazone—CYP2D6—Metabolism—CYP1B1—prostate cancer	1.74e-06	2.02e-05	CbGpPWpGaD
Rosiglitazone—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CD—prostate cancer	1.73e-06	2.01e-05	CbGpPWpGaD
Rosiglitazone—CYP2C9—Metabolism—CYP1B1—prostate cancer	1.73e-06	2e-05	CbGpPWpGaD
Rosiglitazone—CYP2C19—Metabolism—RXRA—prostate cancer	1.72e-06	1.99e-05	CbGpPWpGaD
Rosiglitazone—CYP2C8—Metabolism—TYMS—prostate cancer	1.72e-06	1.99e-05	CbGpPWpGaD
Rosiglitazone—PTGS1—Metabolism—PIK3CD—prostate cancer	1.72e-06	1.99e-05	CbGpPWpGaD
Rosiglitazone—CYP2A6—Metabolism—CREBBP—prostate cancer	1.71e-06	1.98e-05	CbGpPWpGaD
Rosiglitazone—ALB—Metabolism—TYMS—prostate cancer	1.71e-06	1.98e-05	CbGpPWpGaD
Rosiglitazone—CYP2C8—Metabolism—GSTM1—prostate cancer	1.7e-06	1.97e-05	CbGpPWpGaD
Rosiglitazone—ALB—Hemostasis—TGFB1—prostate cancer	1.7e-06	1.97e-05	CbGpPWpGaD
Rosiglitazone—CYP2D6—Metabolism—GGT1—prostate cancer	1.69e-06	1.96e-05	CbGpPWpGaD
Rosiglitazone—ALB—Metabolism—GSTM1—prostate cancer	1.69e-06	1.96e-05	CbGpPWpGaD
Rosiglitazone—SLCO1B1—Metabolism—PIK3CB—prostate cancer	1.68e-06	1.95e-05	CbGpPWpGaD
Rosiglitazone—CYP2C9—Metabolism—GGT1—prostate cancer	1.67e-06	1.94e-05	CbGpPWpGaD
Rosiglitazone—CYP2C19—Metabolism of lipids and lipoproteins—PTEN—prostate cancer	1.67e-06	1.94e-05	CbGpPWpGaD
Rosiglitazone—CYP1A2—Metabolism—NCOA2—prostate cancer	1.67e-06	1.94e-05	CbGpPWpGaD
Rosiglitazone—CYP2C8—Metabolism—LPL—prostate cancer	1.67e-06	1.93e-05	CbGpPWpGaD
Rosiglitazone—SLCO1B1—Metabolism—PTGS2—prostate cancer	1.67e-06	1.93e-05	CbGpPWpGaD
Rosiglitazone—CYP2D6—Metabolism—NCOA1—prostate cancer	1.66e-06	1.93e-05	CbGpPWpGaD
Rosiglitazone—ALB—Metabolism—LPL—prostate cancer	1.66e-06	1.92e-05	CbGpPWpGaD
Rosiglitazone—CYP2C19—Metabolism—COMT—prostate cancer	1.66e-06	1.92e-05	CbGpPWpGaD
Rosiglitazone—CYP2C19—Metabolism—GSTP1—prostate cancer	1.65e-06	1.91e-05	CbGpPWpGaD
Rosiglitazone—CYP2C9—Metabolism—NCOA1—prostate cancer	1.65e-06	1.91e-05	CbGpPWpGaD
Rosiglitazone—CYP2D6—Metabolism—CYP19A1—prostate cancer	1.64e-06	1.9e-05	CbGpPWpGaD
Rosiglitazone—CYP2C9—Metabolism—CYP19A1—prostate cancer	1.63e-06	1.88e-05	CbGpPWpGaD
Rosiglitazone—CYP2C19—Metabolism—ITPR1—prostate cancer	1.62e-06	1.88e-05	CbGpPWpGaD
Rosiglitazone—CYP2A6—Metabolism—PIK3CD—prostate cancer	1.62e-06	1.88e-05	CbGpPWpGaD
Rosiglitazone—PTGS1—Metabolism—NOS3—prostate cancer	1.62e-06	1.88e-05	CbGpPWpGaD
Rosiglitazone—CYP2C8—Metabolism—CYP1A1—prostate cancer	1.61e-06	1.87e-05	CbGpPWpGaD
Rosiglitazone—ALB—Metabolism—CYP1A1—prostate cancer	1.6e-06	1.86e-05	CbGpPWpGaD
Rosiglitazone—CYP2C8—Metabolism—ERCC2—prostate cancer	1.6e-06	1.85e-05	CbGpPWpGaD
Rosiglitazone—CYP2C19—Metabolism of lipids and lipoproteins—EP300—prostate cancer	1.6e-06	1.85e-05	CbGpPWpGaD
Rosiglitazone—CYP1A2—Metabolism—SLC5A5—prostate cancer	1.6e-06	1.85e-05	CbGpPWpGaD
Rosiglitazone—ALB—Metabolism—ERCC2—prostate cancer	1.59e-06	1.84e-05	CbGpPWpGaD
Rosiglitazone—CYP2D6—Metabolism—RXRA—prostate cancer	1.58e-06	1.83e-05	CbGpPWpGaD
Rosiglitazone—ALB—Hemostasis—KRAS—prostate cancer	1.57e-06	1.82e-05	CbGpPWpGaD
Rosiglitazone—CYP2C9—Metabolism—RXRA—prostate cancer	1.57e-06	1.82e-05	CbGpPWpGaD
Rosiglitazone—CYP1A2—Metabolism—CYP2E1—prostate cancer	1.56e-06	1.81e-05	CbGpPWpGaD
Rosiglitazone—CYP1A2—Metabolism—NQO1—prostate cancer	1.54e-06	1.79e-05	CbGpPWpGaD
Rosiglitazone—CYP2C19—Metabolism—TYMS—prostate cancer	1.53e-06	1.78e-05	CbGpPWpGaD
Rosiglitazone—CYP2A6—Metabolism—NOS3—prostate cancer	1.53e-06	1.78e-05	CbGpPWpGaD
Rosiglitazone—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—prostate cancer	1.53e-06	1.77e-05	CbGpPWpGaD
Rosiglitazone—CYP2D6—Metabolism—COMT—prostate cancer	1.52e-06	1.77e-05	CbGpPWpGaD
Rosiglitazone—CYP1A2—Metabolism—TH—prostate cancer	1.52e-06	1.76e-05	CbGpPWpGaD
Rosiglitazone—CYP2D6—Metabolism—GSTP1—prostate cancer	1.52e-06	1.76e-05	CbGpPWpGaD
Rosiglitazone—CYP2C19—Metabolism—GSTM1—prostate cancer	1.52e-06	1.76e-05	CbGpPWpGaD
Rosiglitazone—CYP2C9—Metabolism—COMT—prostate cancer	1.51e-06	1.75e-05	CbGpPWpGaD
Rosiglitazone—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CB—prostate cancer	1.51e-06	1.75e-05	CbGpPWpGaD
Rosiglitazone—CYP2C9—Metabolism—GSTP1—prostate cancer	1.5e-06	1.74e-05	CbGpPWpGaD
Rosiglitazone—CYP1A2—Metabolism—CYP3A4—prostate cancer	1.5e-06	1.74e-05	CbGpPWpGaD
Rosiglitazone—CYP2C8—Metabolism—MTHFR—prostate cancer	1.5e-06	1.74e-05	CbGpPWpGaD
Rosiglitazone—PTGS1—Metabolism—PIK3CB—prostate cancer	1.5e-06	1.73e-05	CbGpPWpGaD
Rosiglitazone—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—prostate cancer	1.5e-06	1.73e-05	CbGpPWpGaD
Rosiglitazone—CYP2D6—Metabolism—ITPR1—prostate cancer	1.49e-06	1.73e-05	CbGpPWpGaD
Rosiglitazone—ALB—Metabolism—MTHFR—prostate cancer	1.49e-06	1.73e-05	CbGpPWpGaD
Rosiglitazone—CYP2C19—Metabolism—LPL—prostate cancer	1.49e-06	1.72e-05	CbGpPWpGaD
Rosiglitazone—PTGS1—Metabolism—PTGS2—prostate cancer	1.48e-06	1.72e-05	CbGpPWpGaD
Rosiglitazone—CYP2C9—Metabolism—ITPR1—prostate cancer	1.48e-06	1.72e-05	CbGpPWpGaD
Rosiglitazone—CYP1A2—Metabolism—CYP1B1—prostate cancer	1.48e-06	1.71e-05	CbGpPWpGaD
Rosiglitazone—CYP2C8—Metabolism—PPARA—prostate cancer	1.47e-06	1.71e-05	CbGpPWpGaD
Rosiglitazone—ALB—Metabolism—PPARA—prostate cancer	1.46e-06	1.7e-05	CbGpPWpGaD
Rosiglitazone—CYP2C9—Metabolism of lipids and lipoproteins—EP300—prostate cancer	1.46e-06	1.69e-05	CbGpPWpGaD
Rosiglitazone—SLCO1B1—Metabolism—PTEN—prostate cancer	1.45e-06	1.68e-05	CbGpPWpGaD
Rosiglitazone—ALB—Hemostasis—PIK3CA—prostate cancer	1.44e-06	1.67e-05	CbGpPWpGaD
Rosiglitazone—CYP2C19—Metabolism—CYP1A1—prostate cancer	1.44e-06	1.67e-05	CbGpPWpGaD
Rosiglitazone—CYP1A2—Metabolism—GGT1—prostate cancer	1.43e-06	1.66e-05	CbGpPWpGaD
Rosiglitazone—CYP2C19—Metabolism—ERCC2—prostate cancer	1.43e-06	1.65e-05	CbGpPWpGaD
Rosiglitazone—CYP2A6—Metabolism—PIK3CB—prostate cancer	1.41e-06	1.64e-05	CbGpPWpGaD
Rosiglitazone—CYP2D6—Metabolism—TYMS—prostate cancer	1.41e-06	1.64e-05	CbGpPWpGaD
Rosiglitazone—CYP1A2—Metabolism—NCOA1—prostate cancer	1.41e-06	1.63e-05	CbGpPWpGaD
Rosiglitazone—CYP2A6—Metabolism—PTGS2—prostate cancer	1.4e-06	1.62e-05	CbGpPWpGaD
Rosiglitazone—CYP2C9—Metabolism—TYMS—prostate cancer	1.4e-06	1.62e-05	CbGpPWpGaD
Rosiglitazone—ALB—Hemostasis—TP53—prostate cancer	1.4e-06	1.62e-05	CbGpPWpGaD
Rosiglitazone—CYP2D6—Metabolism—GSTM1—prostate cancer	1.39e-06	1.62e-05	CbGpPWpGaD
Rosiglitazone—CYP1A2—Metabolism—CYP19A1—prostate cancer	1.39e-06	1.61e-05	CbGpPWpGaD
Rosiglitazone—SLCO1B1—Metabolism—EP300—prostate cancer	1.39e-06	1.61e-05	CbGpPWpGaD
Rosiglitazone—CYP2C8—Metabolism—CAV1—prostate cancer	1.38e-06	1.6e-05	CbGpPWpGaD
Rosiglitazone—CYP2C9—Metabolism—GSTM1—prostate cancer	1.38e-06	1.6e-05	CbGpPWpGaD
Rosiglitazone—ALB—Metabolism—CAV1—prostate cancer	1.38e-06	1.6e-05	CbGpPWpGaD
Rosiglitazone—CYP2D6—Metabolism—LPL—prostate cancer	1.37e-06	1.59e-05	CbGpPWpGaD
Rosiglitazone—PPARG—Gene Expression—AKT1—prostate cancer	1.37e-06	1.59e-05	CbGpPWpGaD
Rosiglitazone—CYP2C9—Metabolism—LPL—prostate cancer	1.36e-06	1.57e-05	CbGpPWpGaD
Rosiglitazone—CYP1A2—Metabolism—RXRA—prostate cancer	1.34e-06	1.55e-05	CbGpPWpGaD
Rosiglitazone—CYP2C19—Metabolism—MTHFR—prostate cancer	1.34e-06	1.55e-05	CbGpPWpGaD
Rosiglitazone—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CA—prostate cancer	1.32e-06	1.53e-05	CbGpPWpGaD
Rosiglitazone—CYP2D6—Metabolism—CYP1A1—prostate cancer	1.32e-06	1.53e-05	CbGpPWpGaD
Rosiglitazone—ALB—Metabolism of lipids and lipoproteins—PIK3CA—prostate cancer	1.32e-06	1.52e-05	CbGpPWpGaD
Rosiglitazone—CYP2C19—Metabolism—PPARA—prostate cancer	1.31e-06	1.52e-05	CbGpPWpGaD
Rosiglitazone—CYP2D6—Metabolism—ERCC2—prostate cancer	1.31e-06	1.52e-05	CbGpPWpGaD
Rosiglitazone—CYP2C9—Metabolism—CYP1A1—prostate cancer	1.31e-06	1.52e-05	CbGpPWpGaD
Rosiglitazone—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—prostate cancer	1.3e-06	1.51e-05	CbGpPWpGaD
Rosiglitazone—PPARG—Metabolism—PIK3CA—prostate cancer	1.3e-06	1.51e-05	CbGpPWpGaD
Rosiglitazone—CYP2C9—Metabolism—ERCC2—prostate cancer	1.3e-06	1.51e-05	CbGpPWpGaD
Rosiglitazone—PTGS1—Metabolism—PTEN—prostate cancer	1.29e-06	1.5e-05	CbGpPWpGaD
Rosiglitazone—CYP1A2—Metabolism—COMT—prostate cancer	1.29e-06	1.5e-05	CbGpPWpGaD
Rosiglitazone—CYP1A2—Metabolism—GSTP1—prostate cancer	1.29e-06	1.49e-05	CbGpPWpGaD
Rosiglitazone—CYP1A2—Metabolism—ITPR1—prostate cancer	1.26e-06	1.47e-05	CbGpPWpGaD
Rosiglitazone—CYP2C8—Metabolism—PIK3CG—prostate cancer	1.26e-06	1.46e-05	CbGpPWpGaD
Rosiglitazone—ALB—Metabolism—PIK3CG—prostate cancer	1.25e-06	1.45e-05	CbGpPWpGaD
Rosiglitazone—CYP1A2—Metabolism of lipids and lipoproteins—EP300—prostate cancer	1.24e-06	1.44e-05	CbGpPWpGaD
Rosiglitazone—CYP2C19—Metabolism—CAV1—prostate cancer	1.24e-06	1.43e-05	CbGpPWpGaD
Rosiglitazone—PTGS1—Metabolism—EP300—prostate cancer	1.23e-06	1.43e-05	CbGpPWpGaD
Rosiglitazone—CYP2D6—Metabolism—MTHFR—prostate cancer	1.23e-06	1.43e-05	CbGpPWpGaD
Rosiglitazone—CYP2A6—Metabolism—PTEN—prostate cancer	1.22e-06	1.42e-05	CbGpPWpGaD
Rosiglitazone—CYP2C9—Metabolism—MTHFR—prostate cancer	1.22e-06	1.42e-05	CbGpPWpGaD
Rosiglitazone—CYP2D6—Metabolism—PPARA—prostate cancer	1.21e-06	1.4e-05	CbGpPWpGaD
Rosiglitazone—CYP2C9—Metabolism—PPARA—prostate cancer	1.2e-06	1.39e-05	CbGpPWpGaD
Rosiglitazone—CYP1A2—Metabolism—TYMS—prostate cancer	1.19e-06	1.39e-05	CbGpPWpGaD
Rosiglitazone—CYP2C8—Metabolism—INS—prostate cancer	1.19e-06	1.38e-05	CbGpPWpGaD
Rosiglitazone—ALB—Metabolism—INS—prostate cancer	1.19e-06	1.38e-05	CbGpPWpGaD
Rosiglitazone—CYP1A2—Metabolism—GSTM1—prostate cancer	1.18e-06	1.37e-05	CbGpPWpGaD
Rosiglitazone—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CA—prostate cancer	1.18e-06	1.37e-05	CbGpPWpGaD
Rosiglitazone—ALB—Hemostasis—AKT1—prostate cancer	1.18e-06	1.37e-05	CbGpPWpGaD
Rosiglitazone—CYP2C8—Metabolism—CREBBP—prostate cancer	1.17e-06	1.36e-05	CbGpPWpGaD
Rosiglitazone—CYP2A6—Metabolism—EP300—prostate cancer	1.17e-06	1.35e-05	CbGpPWpGaD
Rosiglitazone—ALB—Metabolism—CREBBP—prostate cancer	1.16e-06	1.35e-05	CbGpPWpGaD
Rosiglitazone—CYP1A2—Metabolism—LPL—prostate cancer	1.16e-06	1.34e-05	CbGpPWpGaD
Rosiglitazone—CYP2D6—Metabolism—CAV1—prostate cancer	1.14e-06	1.32e-05	CbGpPWpGaD
Rosiglitazone—CYP2C9—Metabolism—CAV1—prostate cancer	1.13e-06	1.31e-05	CbGpPWpGaD
Rosiglitazone—CYP2C19—Metabolism—PIK3CG—prostate cancer	1.13e-06	1.3e-05	CbGpPWpGaD
Rosiglitazone—CYP1A2—Metabolism—CYP1A1—prostate cancer	1.12e-06	1.3e-05	CbGpPWpGaD
Rosiglitazone—CYP1A2—Metabolism—ERCC2—prostate cancer	1.11e-06	1.29e-05	CbGpPWpGaD
Rosiglitazone—CYP2C8—Metabolism—PIK3CD—prostate cancer	1.11e-06	1.29e-05	CbGpPWpGaD
Rosiglitazone—ALB—Metabolism—PIK3CD—prostate cancer	1.1e-06	1.28e-05	CbGpPWpGaD
Rosiglitazone—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—prostate cancer	1.08e-06	1.25e-05	CbGpPWpGaD
Rosiglitazone—CYP2C19—Metabolism—INS—prostate cancer	1.07e-06	1.24e-05	CbGpPWpGaD
Rosiglitazone—PPARG—Metabolism—AKT1—prostate cancer	1.06e-06	1.23e-05	CbGpPWpGaD
Rosiglitazone—CYP2C8—Metabolism—NOS3—prostate cancer	1.05e-06	1.21e-05	CbGpPWpGaD
Rosiglitazone—CYP1A2—Metabolism—MTHFR—prostate cancer	1.04e-06	1.21e-05	CbGpPWpGaD
Rosiglitazone—CYP2C19—Metabolism—CREBBP—prostate cancer	1.04e-06	1.21e-05	CbGpPWpGaD
Rosiglitazone—ALB—Metabolism—NOS3—prostate cancer	1.04e-06	1.21e-05	CbGpPWpGaD
Rosiglitazone—CYP2D6—Metabolism—PIK3CG—prostate cancer	1.04e-06	1.2e-05	CbGpPWpGaD
Rosiglitazone—CYP2C9—Metabolism—PIK3CG—prostate cancer	1.03e-06	1.19e-05	CbGpPWpGaD
Rosiglitazone—SLCO1B1—Metabolism—PIK3CA—prostate cancer	1.03e-06	1.19e-05	CbGpPWpGaD
Rosiglitazone—CYP1A2—Metabolism—PPARA—prostate cancer	1.02e-06	1.19e-05	CbGpPWpGaD
Rosiglitazone—CYP2C19—Metabolism—PIK3CD—prostate cancer	9.9e-07	1.15e-05	CbGpPWpGaD
Rosiglitazone—CYP2D6—Metabolism—INS—prostate cancer	9.8e-07	1.14e-05	CbGpPWpGaD
Rosiglitazone—CYP2C9—Metabolism—INS—prostate cancer	9.72e-07	1.13e-05	CbGpPWpGaD
Rosiglitazone—CYP2C8—Metabolism—PIK3CB—prostate cancer	9.66e-07	1.12e-05	CbGpPWpGaD
Rosiglitazone—CYP1A2—Metabolism—CAV1—prostate cancer	9.63e-07	1.12e-05	CbGpPWpGaD
Rosiglitazone—ALB—Metabolism—PIK3CB—prostate cancer	9.61e-07	1.11e-05	CbGpPWpGaD
Rosiglitazone—CYP2D6—Metabolism—CREBBP—prostate cancer	9.6e-07	1.11e-05	CbGpPWpGaD
Rosiglitazone—CYP2C8—Metabolism—PTGS2—prostate cancer	9.57e-07	1.11e-05	CbGpPWpGaD
Rosiglitazone—ALB—Metabolism—PTGS2—prostate cancer	9.52e-07	1.1e-05	CbGpPWpGaD
Rosiglitazone—CYP2C9—Metabolism—CREBBP—prostate cancer	9.52e-07	1.1e-05	CbGpPWpGaD
Rosiglitazone—CYP2C19—Metabolism—NOS3—prostate cancer	9.34e-07	1.08e-05	CbGpPWpGaD
Rosiglitazone—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—prostate cancer	9.2e-07	1.07e-05	CbGpPWpGaD
Rosiglitazone—PTGS1—Metabolism—PIK3CA—prostate cancer	9.12e-07	1.06e-05	CbGpPWpGaD
Rosiglitazone—CYP2D6—Metabolism—PIK3CD—prostate cancer	9.1e-07	1.06e-05	CbGpPWpGaD
Rosiglitazone—CYP2C9—Metabolism—PIK3CD—prostate cancer	9.02e-07	1.05e-05	CbGpPWpGaD
Rosiglitazone—CYP1A2—Metabolism—PIK3CG—prostate cancer	8.77e-07	1.02e-05	CbGpPWpGaD
Rosiglitazone—CYP2C19—Metabolism—PIK3CB—prostate cancer	8.63e-07	1e-05	CbGpPWpGaD
Rosiglitazone—CYP2A6—Metabolism—PIK3CA—prostate cancer	8.62e-07	1e-05	CbGpPWpGaD
Rosiglitazone—CYP2D6—Metabolism—NOS3—prostate cancer	8.59e-07	9.96e-06	CbGpPWpGaD
Rosiglitazone—CYP2C19—Metabolism—PTGS2—prostate cancer	8.55e-07	9.91e-06	CbGpPWpGaD
Rosiglitazone—CYP2C9—Metabolism—NOS3—prostate cancer	8.52e-07	9.88e-06	CbGpPWpGaD
Rosiglitazone—SLCO1B1—Metabolism—AKT1—prostate cancer	8.37e-07	9.71e-06	CbGpPWpGaD
Rosiglitazone—CYP2C8—Metabolism—PTEN—prostate cancer	8.35e-07	9.68e-06	CbGpPWpGaD
Rosiglitazone—ALB—Metabolism—PTEN—prostate cancer	8.3e-07	9.62e-06	CbGpPWpGaD
Rosiglitazone—CYP1A2—Metabolism—INS—prostate cancer	8.3e-07	9.62e-06	CbGpPWpGaD
Rosiglitazone—CYP1A2—Metabolism—CREBBP—prostate cancer	8.13e-07	9.43e-06	CbGpPWpGaD
Rosiglitazone—CYP2C8—Metabolism—EP300—prostate cancer	7.96e-07	9.23e-06	CbGpPWpGaD
Rosiglitazone—CYP2D6—Metabolism—PIK3CB—prostate cancer	7.93e-07	9.2e-06	CbGpPWpGaD
Rosiglitazone—ALB—Metabolism—EP300—prostate cancer	7.92e-07	9.18e-06	CbGpPWpGaD
Rosiglitazone—CYP2C9—Metabolism—PIK3CB—prostate cancer	7.86e-07	9.12e-06	CbGpPWpGaD
Rosiglitazone—CYP2D6—Metabolism—PTGS2—prostate cancer	7.86e-07	9.11e-06	CbGpPWpGaD
Rosiglitazone—CYP2C9—Metabolism—PTGS2—prostate cancer	7.79e-07	9.03e-06	CbGpPWpGaD
Rosiglitazone—CYP1A2—Metabolism—PIK3CD—prostate cancer	7.71e-07	8.94e-06	CbGpPWpGaD
Rosiglitazone—CYP2C19—Metabolism—PTEN—prostate cancer	7.45e-07	8.64e-06	CbGpPWpGaD
Rosiglitazone—PTGS1—Metabolism—AKT1—prostate cancer	7.45e-07	8.64e-06	CbGpPWpGaD
Rosiglitazone—CYP1A2—Metabolism—NOS3—prostate cancer	7.28e-07	8.44e-06	CbGpPWpGaD
Rosiglitazone—CYP2C19—Metabolism—EP300—prostate cancer	7.11e-07	8.24e-06	CbGpPWpGaD
Rosiglitazone—CYP2A6—Metabolism—AKT1—prostate cancer	7.05e-07	8.17e-06	CbGpPWpGaD
Rosiglitazone—CYP2D6—Metabolism—PTEN—prostate cancer	6.86e-07	7.95e-06	CbGpPWpGaD
Rosiglitazone—CYP2C9—Metabolism—PTEN—prostate cancer	6.8e-07	7.88e-06	CbGpPWpGaD
Rosiglitazone—CYP1A2—Metabolism—PIK3CB—prostate cancer	6.72e-07	7.79e-06	CbGpPWpGaD
Rosiglitazone—CYP1A2—Metabolism—PTGS2—prostate cancer	6.66e-07	7.72e-06	CbGpPWpGaD
Rosiglitazone—CYP2D6—Metabolism—EP300—prostate cancer	6.54e-07	7.58e-06	CbGpPWpGaD
Rosiglitazone—CYP2C9—Metabolism—EP300—prostate cancer	6.48e-07	7.51e-06	CbGpPWpGaD
Rosiglitazone—CYP2C8—Metabolism—PIK3CA—prostate cancer	5.89e-07	6.83e-06	CbGpPWpGaD
Rosiglitazone—ALB—Metabolism—PIK3CA—prostate cancer	5.86e-07	6.79e-06	CbGpPWpGaD
Rosiglitazone—CYP1A2—Metabolism—PTEN—prostate cancer	5.81e-07	6.73e-06	CbGpPWpGaD
Rosiglitazone—CYP1A2—Metabolism—EP300—prostate cancer	5.54e-07	6.42e-06	CbGpPWpGaD
Rosiglitazone—CYP2C19—Metabolism—PIK3CA—prostate cancer	5.26e-07	6.1e-06	CbGpPWpGaD
Rosiglitazone—CYP2D6—Metabolism—PIK3CA—prostate cancer	4.84e-07	5.61e-06	CbGpPWpGaD
Rosiglitazone—CYP2C8—Metabolism—AKT1—prostate cancer	4.81e-07	5.58e-06	CbGpPWpGaD
Rosiglitazone—CYP2C9—Metabolism—PIK3CA—prostate cancer	4.79e-07	5.56e-06	CbGpPWpGaD
Rosiglitazone—ALB—Metabolism—AKT1—prostate cancer	4.78e-07	5.55e-06	CbGpPWpGaD
Rosiglitazone—CYP2C19—Metabolism—AKT1—prostate cancer	4.3e-07	4.98e-06	CbGpPWpGaD
Rosiglitazone—CYP1A2—Metabolism—PIK3CA—prostate cancer	4.1e-07	4.75e-06	CbGpPWpGaD
Rosiglitazone—CYP2D6—Metabolism—AKT1—prostate cancer	3.95e-07	4.58e-06	CbGpPWpGaD
Rosiglitazone—CYP2C9—Metabolism—AKT1—prostate cancer	3.92e-07	4.54e-06	CbGpPWpGaD
Rosiglitazone—CYP1A2—Metabolism—AKT1—prostate cancer	3.35e-07	3.88e-06	CbGpPWpGaD
